Key result
Biomarkers involved in neurohormonal activation, myocardial injury, and inflammation may help identify LVAD patients at increased risk of adverse events and highlight new therapeutic targets.
Why the study?
LVAD use induces pathophysiological modifications linked to complications, and evaluating biomarkers across various pathways could identify high-risk patients, guide management, and highlight new therapeutic targets.
This review highlights the potential of various biomarkers to predict adverse events like right ventricular failure, thromboembolism, and bleeding in LVAD patients, potentially guiding closer follow-up and novel therapeutic targets.
May aid risk stratification for LVAD complications; leaves open prospective validation before clinical adoption.
Left ventricular assist devices (LVADs) have been representing a cornerstone therapy for patients with end-stage heart failure during the last decades. However, their use induces several pathophysiological modifications which are partially responsible for the complications that typically characterize these patients, such as right ventricular failure, thromboembolic events, as well as bleedings. During the last years, biomarkers involved in the pathways of neurohormonal activation, myocardial injury, adverse remodeling, oxidative stress and systemic inflammation have raised attention. The search and analysis of potential biomarkers in LVAD patients could lead to the identification of a subset of patients with an increased risk of developing these adverse events. This could then promote a closer follow-up as well as therapeutic modifications. Furthermore, it might highlight some new therapeutic pharmacological targets that could lead to improved long-term survival. The aim of this review is to provide current evidence on the role of different biomarkers in patients with LVAD, in particular highlighting their possible implications in clinical practice.
No takes yet. Share an insight, caveat, or question.
Sciaccaluga et al. (2022) conducted a review in End-stage heart failure with Left Ventricular Assist Device (LVAD). Biomarkers was evaluated. Biomarkers involved in neurohormonal activation, myocardial injury, and inflammation may help identify LVAD patients at increased risk of adverse events and highlight new therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: